Associated with immune response, elevated N-acetylmuramoyl-L-alanine amidase levels were correlated with an increased risk of intracranial hemorrhage (ICH) postrecombinant tissue plasminogen activator (post-rtPA) treatment in stroke patients, underscoring its value in predicting hemorrhagic complications. The gene discussed is PGLYRP2; the disease is stroke disorder.